Purple Biotech Ltd (PPBT)

NASDAQ: PPBT · Real-Time Price · USD
2.720
+0.038 (1.43%)
Apr 3, 2025, 3:35 PM EDT - Market open
1.43%
Market Cap 6.86M
Revenue (ttm) n/a
Net Income (ttm) -7.24M
Shares Out 529.64M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,889
Open 2.700
Previous Close 2.682
Day's Range 2.640 - 2.740
52-Week Range 2.000 - 20.600
Beta 0.29
Analysts Strong Buy
Price Target 33.00 (+1,113.24%)
Earnings Date Mar 10, 2025

About PPBT

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin recept... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 9
Stock Exchange NASDAQ
Ticker Symbol PPBT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PPBT stock is "Strong Buy" and the 12-month stock price forecast is $33.0.

Price Target
$33.0
(1,113.24% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Completed successful clinical trials for CM24 and NT21 9 oncology assets , demonstrating clinical benefit s and identifying potential biomarkers

24 days ago - GlobeNewsWire

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...

6 weeks ago - GlobeNewsWire

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overco...

4 months ago - GlobeNewsWire

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overco...

4 months ago - GlobeNewsWire

Why Is Purple Biotech Stock Trading Higher On Monday?

On Monday, Purple Biotech Ltd PPBT reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with p...

4 months ago - Benzinga

Purple Biotech Reports Third Quarter 2024 Financial Results

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identif...

4 months ago - GlobeNewsWire

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24

5 months ago - GlobeNewsWire

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CAPTN-3 demonstrates s ustained tumor regression in a triple negative breast cancer in-vivo model ; A dose dependent ac tivity and a synergistic effect of the engage r arm s also seen in non-small cel...

5 months ago - GlobeNewsWire

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer

6 months ago - GlobeNewsWire

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

REHOVOT, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overc...

7 months ago - GlobeNewsWire

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) --   Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that over...

7 months ago - GlobeNewsWire

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology ( ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, p...

8 months ago - GlobeNewsWire

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies t...

9 months ago - GlobeNewsWire

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies t...

9 months ago - GlobeNewsWire

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek ...

9 months ago - GlobeNewsWire

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek t...

9 months ago - GlobeNewsWire

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

REHOVOT, Israel, June 27, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies t...

10 months ago - GlobeNewsWire

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

REHOVOT, Israel, June 01, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harne...

10 months ago - GlobeNewsWire

Purple Biotech Reports First Quarter 2024 Financial Results

CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 – Interim results to be Announced June 1, 2024 CM24 Phase 2 Pancreatic Cancer Interim D...

11 months ago - GlobeNewsWire

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study

1 year ago - GlobeNewsWire

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which incre...

1 year ago - GlobeNewsWire

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harne...

1 year ago - GlobeNewsWire

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEW...

1 year ago - GlobeNewsWire

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) --   Purple Biotech Ltd . ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), ...

1 year ago - GlobeNewsWire

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes...

1 year ago - GlobeNewsWire